DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List , M.D.

- Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Servier Eligible to Receive Milestones and Royalties Based on Program Success - Precision to Host Conference Call and